October 2020
- Nov 2, 2020
- 1 min read
Updated: Jan 8
Synendos Therapeutics has been awarded of an Innosuisse Innovation Grant in collaboration with the group of Prof. J. Gertsch at the University of Bern. The funded project aims to characterize the new drug target of SERIs and to perform other explorative activities on biology and pharmacology of SERIs. The grant (ca. CHF 1m) has a duration of 3 years.
